Prion protein is required for tumor necrosis factor α (TNFα)-triggered nuclear factor κB (NF-κB) signaling and cytokine production

Gui-Ru Wu,Tian-Chen Mu,Zhen-Xing Gao,Jun Wang,Man-Sun Sy,Chao-Yang Li
DOI: https://doi.org/10.1074/jbc.M117.787283
IF: 5.485
2017-01-01
Journal of Biological Chemistry
Abstract:The expression of normal cellular prion protein (PrP) is required for the pathogenesis of prion diseases. However, the physiological functions of PrP remain ambiguous. Here, we identified PrP as being critical for tumor necrosis factor (TNF) -triggered signaling in a human melanoma cell line, M2, and a pancreatic ductal cell adenocarcinoma cell line, BxPC-3. In M2 cells, TNF up-regulates the expression of p-IB-kinase / (p-IKK/), p-p65, and p-JNK, but down-regulates the IB protein, all of which are downstream signaling intermediates in the TNF receptor signaling cascade. When PRNP is deleted in M2 cells, the effects of TNF are no longer detectable. More importantly, p-p65 and p-JNK responses are restored when PRNP is reintroduced into the PRNP null cells. TNF also activates NF-B and increases TNF production in wild-type M2 cells, but not in PrP-null M2 cells. Similar results are obtained in the BxPC-3 cells. Moreover, TNF activation of NF-B requires ubiquitination of receptor-interacting serine/threonine kinase 1 (RIP1) and TNF receptor-associated factor 2 (TRAF2). TNF treatment increases the binding between PrP and the deubiquitinase tumor suppressor cylindromatosis (CYLD), in these treated cells, binding of CYLD to RIP1 and TRAF2 is reduced. We conclude that PrP traps CYLD, preventing it from binding and deubiquitinating RIP1 and TRAF2. Our findings reveal that PrP enhances the responses to TNF, promoting proinflammatory cytokine production, which may contribute to inflammation and tumorigenesis.
What problem does this paper attempt to address?